CN113874399B - 抗ror1/抗cd3双特异性结合分子 - Google Patents

抗ror1/抗cd3双特异性结合分子 Download PDF

Info

Publication number
CN113874399B
CN113874399B CN202080038180.6A CN202080038180A CN113874399B CN 113874399 B CN113874399 B CN 113874399B CN 202080038180 A CN202080038180 A CN 202080038180A CN 113874399 B CN113874399 B CN 113874399B
Authority
CN
China
Prior art keywords
seq
amino acid
binding domain
nos
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080038180.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN113874399A (zh
Inventor
J·D·沃特金斯
K·杰森
M·柯欧
B·兰努蒂
T-T·沃
J·M·沃特金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Veros Biological Co ltd
Original Assignee
Veros Biological Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veros Biological Co ltd filed Critical Veros Biological Co ltd
Publication of CN113874399A publication Critical patent/CN113874399A/zh
Application granted granted Critical
Publication of CN113874399B publication Critical patent/CN113874399B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080038180.6A 2019-05-23 2020-05-22 抗ror1/抗cd3双特异性结合分子 Active CN113874399B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852039P 2019-05-23 2019-05-23
US62/852,039 2019-05-23
PCT/US2020/034281 WO2020237173A1 (en) 2019-05-23 2020-05-22 Anti-ror1/anti-cd3 bispecific binding molecules

Publications (2)

Publication Number Publication Date
CN113874399A CN113874399A (zh) 2021-12-31
CN113874399B true CN113874399B (zh) 2025-07-11

Family

ID=71078637

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080038180.6A Active CN113874399B (zh) 2019-05-23 2020-05-22 抗ror1/抗cd3双特异性结合分子

Country Status (11)

Country Link
US (1) US20220227866A1 (https=)
EP (1) EP3972999A1 (https=)
JP (1) JP7611171B2 (https=)
KR (1) KR20220012313A (https=)
CN (1) CN113874399B (https=)
AU (1) AU2020277489A1 (https=)
BR (1) BR112021023026A2 (https=)
CA (1) CA3139111A1 (https=)
MX (1) MX2021014193A (https=)
TW (1) TWI899079B (https=)
WO (1) WO2020237173A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504620A (ja) * 2019-12-06 2023-02-06 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物
CA3166286A1 (en) 2020-02-07 2021-08-12 Jeffry D. Watkins Anti-ror1 antibodies and compositions
MX2023009022A (es) * 2021-02-02 2023-10-23 Numab Therapeutics AG Anticuerpos multiespecificos con especificidad para ror1 y cd3.
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023000791A1 (en) * 2021-07-23 2023-01-26 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against ror1 and uses thereof
WO2023056556A1 (en) * 2021-10-07 2023-04-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635475B2 (en) * 2003-02-17 2009-12-22 Tohoku Techno Arch Co., Ltd. Diabody-type bispecific antibody
WO2016055592A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
CN108495864A (zh) * 2016-01-22 2018-09-04 詹森生物科技公司 抗ror1抗体、ror1×cd3双特异性抗体及其使用方法
WO2018237335A1 (en) * 2017-06-23 2018-12-27 VelosBio Inc. IMMUNOCONJUGUATED ROR1 ANTIBODIES
WO2019008379A1 (en) * 2017-07-05 2019-01-10 Ucl Business Plc BISPECIFIC ANTIBODIES DIRECTED AGAINST ROR1 AND CD3

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3489261T3 (pl) * 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP2981281B1 (en) 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CN110627907B (zh) * 2013-11-04 2024-03-29 艾科诺斯科技股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
US10519248B2 (en) * 2014-07-25 2019-12-31 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3
WO2017125897A1 (en) * 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
WO2018140831A2 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
WO2019084060A1 (en) * 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CA3166286A1 (en) * 2020-02-07 2021-08-12 Jeffry D. Watkins Anti-ror1 antibodies and compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635475B2 (en) * 2003-02-17 2009-12-22 Tohoku Techno Arch Co., Ltd. Diabody-type bispecific antibody
WO2016055592A1 (en) * 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
CN108495864A (zh) * 2016-01-22 2018-09-04 詹森生物科技公司 抗ror1抗体、ror1×cd3双特异性抗体及其使用方法
WO2018237335A1 (en) * 2017-06-23 2018-12-27 VelosBio Inc. IMMUNOCONJUGUATED ROR1 ANTIBODIES
WO2019008379A1 (en) * 2017-07-05 2019-01-10 Ucl Business Plc BISPECIFIC ANTIBODIES DIRECTED AGAINST ROR1 AND CD3

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Abstract 1489: Development of a humanized ROR1 x CD3 bispecific DART® molecule for the treatment of solid and liquid tumors;Bhaswati Barat et al.;《Cancer Res.》;20160715;第76卷(第14增刊期);第1-4页 *
An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors;Satyen Harish Gohil et al.;《OncoImmunology》;20170711;第6卷(第7期);第1-12页 *
Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1;Junpeng Qi et al.;《APPLIED BIOLOGICAL SCIENCE》;20180529;第115卷(第24期);第E5467-5476页 *
the making of bispecific antibodies;Ulrich Brinkmann et al.;《Mabs》;20170110;第9卷(第2期);第182-212页 *

Also Published As

Publication number Publication date
KR20220012313A (ko) 2022-02-03
US20220227866A1 (en) 2022-07-21
EP3972999A1 (en) 2022-03-30
AU2020277489A1 (en) 2021-11-25
BR112021023026A2 (pt) 2022-01-04
JP7611171B2 (ja) 2025-01-09
MX2021014193A (es) 2022-01-06
CN113874399A (zh) 2021-12-31
CA3139111A1 (en) 2020-11-26
TW202110887A (zh) 2021-03-16
WO2020237173A1 (en) 2020-11-26
TWI899079B (zh) 2025-10-01
JP2022533418A (ja) 2022-07-22

Similar Documents

Publication Publication Date Title
CN113874399B (zh) 抗ror1/抗cd3双特异性结合分子
JP7551693B2 (ja) ＮＫｐ４６結合タンパク質の可変領域
JP7790754B2 (ja) Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用
US12497454B2 (en) Anti-ROR1 antibodies and compositions
CN111867630A (zh) 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
KR20180095086A (ko) 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
JP2018524326A (ja) 多重特異的ｎｋエンゲイジャータンパク質
WO2015197593A1 (en) MULTISPECIFIC NKp46 BINDING PROTEINS
CN114981301B (zh) Pd1和vegfr2双结合剂
AU2021214622B2 (en) Means and method for modulating immune cell engaging effects.
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
CN117916272A (zh) 多特异性抗原结合蛋白
JP7753401B2 (ja) ヒト化抗ｃｌｅｃ－１ａ抗体及びその抗原結合断片及びそのミメティック
CN121039158A (zh) 新型抗fgfr2抗体
RU2831608C2 (ru) Анти-ror1/анти-cd3 биспецифические связывающие молекулы
JP7851303B2 (ja) ヒトｃｄ３イプシロンに結合する新規なヒト抗体
WO2024131846A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TW202545991A (zh) 抗ｃｄ２８抗體及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant